Long-term follow-up for wet AMD treatment
Part of Eyes & vision clinical trials.
This study checks on the long-term safety and effects of a one-time treatment (EXG102-031) for wet age-related macular degeneration. It is only for people who already received that treatment in a previous study.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have taken the study drug EXG102-031 before in an earlier study (called EXG102-031-111).
- You must be willing to sign a consent form and follow the study's rules.
- You must be able to commit to long-term check-ups.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug, EXG202, injected into the eye to treat wet age-related macular degeneration (wAMD). It is for people who have already had some benefit from standard treatments in the past 6 months.
This trial tests a new gene therapy, EXG202, given as an injection into the eye. It aims to see if the treatment is safe and can help slow vision loss from wet AMD, a condition where abnormal blood vessels leak fluid under the retina.
This trial studies how genes affect response to anti-VEGF injections for a common form of age-related vision loss (wet AMD). It aims to tailor treatment to each patient.
This trial is a long-term follow-up for people who already received the AL-001 eye injection for wet age-related macular degeneration (wet AMD) in an earlier study. It will check how you are doing over time.
This study tests a new medicine called SKG0106, given as an injection into the eye, for people with wet age-related macular degeneration (AMD). It aims to see if it is safe and effective in treating the leaky blood vessels that cause vision loss.
This trial tests a new gene therapy called RRG001 for people with the 'wet' form of age-related macular degeneration. It aims to treat leaky blood vessels in the eye that can cause vision loss, possibly reducing the need for frequent eye injections.
Hear when a new Wet Age-related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.